Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|January 10, 2025

Addressing Social Determinants of Health in Hidradenitis Suppurativa Care

Author(s)Hadar Lev-Tov, MD

Panelist discusses how social determinants of health create significant diagnostic barriers for hidradenitis suppurativa through systemic inequities, limited health care access, and provider knowledge gaps. Health systems can mitigate these challenges through targeted educational, technological, and culturally responsive interventions.

Episodes in this series

1 expert is featured in this series.

EP. 1 Bridging the Gap in Recognizing Early Symptoms of Hidradenitis Suppurativa

1 expert is featured in this series.

EP. 2 Improving HS Diagnosis and Care Through Better Alignment of Staging and Severity

1 expert is featured in this series.

EP. 3 Addressing Social Determinants of Health in Hidradenitis Suppurativa Care

1 expert is featured in this series.

EP. 4 Economic Implications of Diagnostic Delays in Hidradenitis Suppurativa

1 expert is featured in this series.

EP. 5 Strategies for Equitable Access in Hidradenitis Suppurativa

1 expert is featured in this series.

EP. 6 Partnering With Patient Advocacy Groups to Improve HS Awareness and Outcomes

1 expert is featured in this series.

EP. 7 Holistic Care for HS Patients: The Power of Multidisciplinary Models

1 expert is featured in this series.

EP. 8 The Case for HS Centers of Excellence: Evidence for Improved Patient Outcomes

1 expert is featured in this series.

EP. 9 Innovating HS Care: Applying Multidisciplinary Lessons to Diagnosis and Management

1 expert is featured in this series.

EP. 10 The Value Proposition: Justifying the Investment in HS Centers of Excellence

1 expert is featured in this series.

EP. 11 Key Takeaways on HS Care: Multidisciplinary Collaboration and Equity Solutions

1 expert is featured in this series.

EP. 12 Navigating HS Management: The Patient Journey

1 expert is featured in this series.

EP. 13 Advancing HS Outcomes: Resource Prioritization and Success Measurement

1 expert is featured in this series.

EP. 14 Tailoring HS Treatment: The Path to Better Patient Outcomes

Video content above is prompted by the following:

How do social determinants of health create barriers to timely and accurate diagnosis of HS?
What strategies can health systems implement to mitigate these barriers?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Dr Irina Murakhovskaya | Image Credit: Montefiore Einstein

ENERGY Trial Shows Early Fatigue Benefit With Nipocalimab in wAIHA: Irina Murakhovskaya, MD

ByBrooke McCormick,Irina Murakhovskaya, MD

June 26th 2026

CRC animation | Image Credit: Thipphaphone - stock.adobe.com

Early-Life, Parental Factors May Help Explain Rising Early-Onset CRC Rates

ByBrooke McCormick

June 26th 2026

This segment explores how emerging data on oral selective estrogen receptor degraders are being applied in clinical practice for hormone receptor–positive, HER2-negative metastatic breast cancer.

HR-Positive Breast Cancer: Clinical Use of Oral SERDs in Combination vs Monotherapy

ByAdam Brufsky, MD, PhD,Hope Rugo, MD,Dr. Mabel Mardones, MD,Ms. Lori Brisbin, MS, MLS Healthcare Law,Dr. Lisa Raff, PharmD

Published: June 26th 2026 | Updated: June 26th 2026

This segment introduces the evolving treatment landscape in hormone receptor–positive, HER2-negative metastatic breast cancer, with a focus on the growing clinical relevance of ESR1 mutations.

HR-Positive Breast Cancer: Evolving Role of ESR1 Mutations in Endocrine Resistance

ByAdam Brufsky, MD, PhD,Hope Rugo, MD,Dr. Mabel Mardones, MD,Ms. Lori Brisbin, MS, MLS Healthcare Law,Dr. Lisa Raff, PharmD

Published: June 26th 2026 | Updated: June 26th 2026

Stamp that says "FDA Approved" in blue ink. | Image Credit: Surendra - stock.adobe.com

FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer

ByElla Hohmann, MS

June 25th 2026

Trending on AJMC

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

National HIV Testing Day Highlights Expanding PrEP, PEP Access, Persistent Barriers

Treatment Burden, End-of-Life Symptom Gaps in Multiple Myeloma

Health Equity & Access Weekly Roundup: June 26, 2026

Health Care Spending to Hit $9 Trillion by 2034, According to New Analysis